OBIO - NASDAQ
Orchestra BioMed Holdings, Inc.
$3.86
-0.52%Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
At a Glance
Live SnapshotOrchestra BioMed Holdings, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Orchestra BioMed Holdings, Inc. Balance Sheet
OBIO • NASDAQ
| Orchestra BioMed Holdings, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
ASSETS | ||||||
CURRENT ASSETS | ||||||
34.7M | 22.3M | 30.6M | 19.8M | 9.9M | 20.3M | |
71.8M | 44.6M | 57M | 64M | 958K | 15.4M | |
106.5M | 66.8M | 87.6M | 83.8M | 10.9M | 35.8M | |
95K | 92K | 99K | 96K | 121K | 168K | |
95K | 92K | 99K | 96K | 121K | 168K | |
310K | 173K | 146K | 276K | 68K | 69K | |
0.0 | 0.0 | 0.0 | 0.0 | 234K | 227K | |
994K | 2.1M | 1.3M | 533K | 0.0 | 0.0 | |
107.9M | 69.2M | 89.1M | 84.7M | 11.3M | 36.3M | |
NON-CURRENT ASSETS | ||||||
3.2M | 3.5M | 2.8M | 3.7M | 1.1M | 1M | |
2.5M | 2.5M | 2.5M | 2.5M | 398K | 185K | |
1.2M | 1M | 769K | 4.7M | 690K | 626K | |
6.9M | 7M | 6.1M | 10.9M | 2.2M | 1.8M | |
114.9M | 76.2M | 95.2M | 95.6M | 13.5M | 38.1M | |
LIABILITIES | ||||||
CURRENT LIABILITIES | ||||||
6.1M | 5.1M | 2.9M | 4M | 2M | 1.8M | |
6.1M | 5.1M | 2.9M | 4M | 2M | 1.8M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 67K | |
0.0 | 3.5M | 2.5M | 2.9M | 1.9M | 540K | |
751K | 0.0 | 0.0 | 0.0 | 2M | 4M | |
0.0 | 550K | 649K | 697K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 1K | 67K | |
0.0 | 4.4M | 2.5M | 6.4M | 5.5M | 5.8M | |
9.9M | 2.6M | 2.7M | 4.6M | 780K | 2.2M | |
16.7M | 16.2M | 11.2M | 18.6M | 12.2M | 14.4M | |
NON-CURRENT LIABILITIES | ||||||
936K | 14.3M | 0.0 | 9.5M | 3.7M | 5.5M | |
0.0 | 11M | 14.9M | 13.1M | 16.9M | 15.1M | |
0.0 | 0.0 | -14.9M | 0.0 | 0.0 | 0.0 | |
33.8M | 40K | 14.9M | 196K | 52M | 51.7M | |
34.7M | 27M | 16M | 24.5M | 72.5M | 72.3M | |
0.0 | 2.2M | 1.7M | 2.4M | 0.0 | 0.0 | |
51.5M | 43.2M | 27.2M | 43M | 84.8M | 86.6M | |
SHAREHOLDERS' EQUITY | ||||||
9.8M | 0.0 | 0.0 | 0.0 | 51.5M | 0.0 | |
6K | 4K | 4K | 2K | 160M | 0.0 | |
416.1M | 342.8M | 316.9M | 252.3M | 94.9M | 94.6M | |
-362.6M | -309.9M | -248.9M | -199.7M | -166.1M | -143.1M | |
60K | 52K | -10K | -8K | -211.5M | -2K | |
63.4M | 33M | 68M | 52.5M | -71.2M | -48.5M | |
63.4M | 33M | 68M | 52.5M | -71.2M | -48.5M | |
SUMMARY | ||||||
114.9M | 76.2M | 95.2M | 95.6M | 13.5M | 38.1M | |
74.3M | 47M | 59.5M | 66.5M | 1.4M | 15.6M | |
1.7M | 16.5M | 1.7M | 11.9M | 5.7M | 9.5M | |
-33M | -5.7M | -28.9M | -7.9M | -4.3M | -10.9M | |
53,955,085 | 53,955,085 | 53,955,085 | 53,955,085 | 53,955,085 | 53,955,085 |
SEC Filings
OBIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
S-3 S-3 N/A | October 31, 2025 | October 31, 2025 | ||
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 24, 2025 | 2025 |
Related Guides
Continue your OBIO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.